Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Chuikyo OKs Pricing Plan for Xocova Listing, 100 Billion Yen Threshold for Possible Re-Pricing
February 16, 2023
- Generic Approval Roster Includes at Least 3 AGs; Azilva, Revlimid, Maintate
February 16, 2023
- MHLW Approves First Generics for Azilva, Revlimid towards June Listing
February 16, 2023
- Expert Panel Agrees on Need for Generic Industry Shakeup, Company Criteria Floated
February 16, 2023
- 5-Year Mandatory Stable Supply Rule for Generics under Scrutiny: Expert Panel
February 16, 2023
- Darzquro to Escape CEA-Based Price Tweaks, Padcev Faces Cuts
February 16, 2023
- Pfizer’s Omicron-Tailored Jab for Ages 5-11 on PAFSC Agenda for Feb. 27
February 16, 2023
- PM Vows Collab with Pharma for Drug Discovery; Health Minister on Relyvrio
February 16, 2023
- Daiichi Sankyo’s Nasal Flu Vaccine Up for MHLW Panel Review on February 27
February 15, 2023
- Label Revisions Ordered for GLP-1 Agents to Add New Side Effect Risks
February 15, 2023
- Japan Should Create Drug Discovery Command Tower: Chugai Honorary Chair
February 14, 2023
- Trade Group Calls for Predictability around SaMD Reimbursement: LDP Gathering
February 14, 2023
- J-TEC’s Cell Sheet for Vitiligo Now in Line for Approval in Japan
February 14, 2023
- Japan Extends Paxlovid Shelf Life to 24 Months
February 13, 2023
- Japan Ends Supply of Moderna’s Original COVID Vaccine
February 13, 2023
- Japan Panel Recognizes 10 More Deaths Possibly Linked to COVID Jabs
February 13, 2023
- Japan Cancels 140 Million-Plus Dose Order of Novavax’s COVID Vaccine
February 13, 2023
- Expert Panel’s Proposal Likely to Involve “2-Stage” Reform, Touch on Funding Too: Chairman
February 10, 2023
- Pharma Trade Groups Stress Concern for Re-Pricing Debate over Xocova: Chuikyo
February 9, 2023
- Japan Panel OKs Next COVID Vaccine Rollout This Autumn, Winter
February 9, 2023
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…